

Shingles Vaccine May Not be Cost Effective for 50 Year Olds; The CBCD Reviews a Report

A study published in the Annals of Internal Medicine, suggested that the herpes zoster (HZ) vaccine does not appear to be cost-effective for those aged 50. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, September 16, 2015 /EINPresswire.com/ --

“Infected with the varicella zoster virus (the virus that causes chickenpox and shingles)? The CBCD recommends taking [Gene-Eden-VIR](#) or [Novirin](#).” - Greg Bennett, CBCD

Herpes zoster is a viral disease caused by a herpesvirus known as the varicella zoster virus (VZV). This is the same virus that causes chickenpox. The Zostavax vaccine is used to “roughly cut in half your chances of getting shingles (herpes zoster).” (2) However, a new study suggests that the vaccine may not be cost-effective for individuals in their 50's. Authors of the study, which was published in the Annals of Internal Medicine wrote that the “herpes zoster vaccine for persons aged 50 years does not seem to represent good value according to generally accepted standards.” (1)

The study “estimated the cost-effectiveness of HZ vaccine versus no vaccine in adults aged 50 years ... and found that 25 HZ cases and one postherpetic neuralgia case could be prevented for every 1,000 persons receiving the vaccine at age 50 years. For HZ vaccine versus no vaccine ... the probability that vaccination would be cost-effective was 3% ...” (1) The Center for the Biology of Chronic Disease (CBCD) recommends that individuals take Gene-Eden-VIR or Novirin against the latent shingles virus. These natural products have no known side-effects, are cost-effective, and were designed to help the immune system target the latent form of VZV.



The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the formula is effective against the herpes family of viruses. Varicella Zoster is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the (herpes viruses) ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that, “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

The CDC notes that the varicella zoster virus (VZV), which is a herpes virus, causes both chickenpox and shingles. “After a person recovers from chickenpox, the virus stays dormant (inactive) in the body. For reasons that are not fully known, the virus can reactivate years later, causing shingles.” (4)

Additionally, the CDC adds that “almost 1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. There are an estimated 1 million cases of shingles each year in this country. Anyone who has recovered from chickenpox may develop shingles; even children can get shingles. However the risk of shingles increases as you get older. About half of all cases occur in men and women 60 years old or older.” (4)

Are there treatments currently on the market, which target the Varicella Zoster Virus (VZV)?

Yes there are.

As noted above, there is the Zostavax vaccine. It is an existing vaccine that was found to reduce the risk of developing a shingles outbreak in 60% of those vaccinated. The vaccine also decreases the long-term pain from post-herpetic neuralgia (PHN). In adults vaccinated at age 60 years or older, however, protection from the vaccine decreases within the first 5 years after vaccination. (4)

There are also antiviral drugs, such as Zovirax or Valtrex. However, these medications, when effective, only work to shorten the time of the shingles outbreak. They are ineffective against the latent VZV virus. (3)

Gene-Eden-VIR and Novirin are natural remedies designed to help the immune system target latent herpes viruses, including the VZV. (3)

“We encourage everyone who has had chickenpox to take Gene-Eden-VIR or Novirin. The formula

was designed to help the immune system target the latent VZV." - Greg Bennett, CBCD

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter here: @HananPolansky

References:

(1) ClinicalAdvisor.com - "At age 50, herpes zoster vaccine not cost-effective" Published September 08, 2015.

(2) WebMD.com - Shingles Health Center - Shingles Vaccine

(3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

(4) CDC.gov - "Shingles (Herpes Zoster)" - Prevention & Treatment. Last Reviewed on May 1, 2014.

<http://www.cdc.gov/shingles/about/prevention-treatment.html>

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.



